Topics

Research on Circular RNA Characteristics and Diseases

Intercellular Communication & Diseases Chronic Inflammation Neurodegeneration Cancer Immunotherapy

Circular RNAs are covalently closed RNA molecules produced mainly by back-splicing, in which a downstream splice donor joins an upstream acceptor. They were once treated largely as rare splicing by-products, but high-throughput RNA sequencing and dedicated computational methods revealed abundant, conserved, and tissue-specific circles in animals. Their closed structure lacks free 5-prime and 3-prime ends and often gives greater resistance to exonucleases than linear RNA. Current research examines circRNA biogenesis, localization, turnover, function, and disease association, with particular interest in their stability as biomarkers and their capacity to regulate gene expression[1][2][3].

Biogenesis depends on spliceosomal activity, intronic complementarity such as inverted Alu repeats, and RNA-binding proteins that bring splice sites together or oppose circularization. Exonic circRNAs commonly accumulate in the cytoplasm, whereas some intron-containing circles remain nuclear and influence transcription. Mechanisms include binding proteins, competing for selected microRNAs when sufficiently abundant and rich in binding sites, modulating parental-gene expression, organizing molecular complexes, and in some cases serving as templates for cap-independent translation. A circRNA's function cannot be inferred from circularity or predicted sites alone; investigators must quantify absolute abundance, distinguish the circle from its linear host transcript, demonstrate direct binding, and show a molecular consequence at endogenous concentration[1][2][3].

Disease studies report altered circRNA profiles in cancer, cardiovascular and neurological disorders, diabetes, and inflammatory conditions. Their stability and presence in blood or extracellular vesicles support diagnostic research, while tissue-specific circles may identify cell injury or tumor lineage. Functional studies use junction-targeting oligonucleotides or CRISPR-based disruption of circularization to test effects on proliferation, apoptosis, metastasis, synaptic function, or immune signaling. Engineered circRNAs are also being explored for durable protein production and RNA therapeutics because circularization can extend RNA persistence. However, most proposed clinical biomarkers remain in retrospective cohorts, and many disease-associated circles have not shown incremental value beyond established tests[1][3].

Major gaps arise from measurement and specificity. Reverse transcription can create template-switching artifacts, repetitive sequences complicate alignment, RNase R does not remove every linear RNA, and host-gene changes can mimic circRNA regulation. Rigorous validation should combine divergent-junction PCR, sequencing of the back-splice junction, resistance testing, northern blotting or orthogonal size analysis, and controls for linear transcripts. Perturbation should target the junction or flanking circularization elements and include rescue with a circle that preserves sequence but avoids the intervention. Long-read and single-cell methods can resolve isoforms and cellular origin, while standardized reporting can improve comparison across cohorts. Clinical translation requires prospective validation, reproducible preanalytics, and evidence that manipulating the circle is safe and mechanistically superior to targeting its associated protein or linear RNA pathway Biomarker studies should predefine the circular junction assay, normalization strategy, disease stage, and clinical comparator. Hemolysis, platelet activation, and sample storage can change extracellular RNA measurements and require controls. For therapeutic circles, innate immune sensing, translation fidelity, tissue delivery, and product heterogeneity need direct evaluation. These criteria separate a biologically interesting RNA from a clinically reliable diagnostic or drug platform. Independent cohorts should confirm both analytical stability and decision-relevant clinical performance[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Screening Libraries
  • Kits
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-17026 Gemcitabine
Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, and can modulate autophagy. Gemcitabine induces apoptosis through the activation of p38 MAPK. Gemcitabine demonstrates efficacy in mouse models of pancreatic and breast cancer. Gemcitabine can be used for cancer research, such as pancreatic cancer, non-small cell lung cancer, and breast cancer.
Nucleoside Antimetabolite/Analog   DNA/RNA Synthesis   Autophagy   Apoptosis   p38 MAPK  
Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Digestive System Inflammation   Non-Small Cell Lung Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
301
HY-17371 Oxaliplatin
Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research.
DNA/RNA Synthesis   Apoptosis  
Prostate Cancer   Pancreatic Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer  
237
HY-17565A Bleomycin hydrochloride
Bleomycin hydrochloride is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin hydrochloride is an antitumor antibiotic.
DNA/RNA Synthesis   Antibiotic  
Pancreatic Cancer   Viral Infection  
218
HY-17565 Bleomycin sulfate
Bleomycin sulfate is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin sulfate is an antitumor antibiotic.

Source: Streptomyces verticillus

DNA/RNA Synthesis   Antibiotic  
Pancreatic Cancer   Viral Infection  
218
HY-16561 Resveratrol
Resveratrol (trans-Resveratrol; SRT501) is a CNS-penetrant natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.
DNA/RNA Synthesis   IKK   Autophagy   Mitophagy   Sirtuin   Apoptosis   Bacterial   Fungal   Antibiotic   Keap1-Nrf2  
Neurological, Eye or Ear Disease   Prostate Cancer   Liver Cancer   Bacterial Infection   Fungal Infection   Digestive System Inflammation   Glucose Metabolism   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
175
HY-D0815 Propidium Iodide
Propidium Iodide (PI) is a nuclear staining agent that stains DNA. Propidium Iodide is an analogue of ethidine bromide that emits red fluorescence upon embedding in double-stranded DNA. Propidium Iodide cannot pass through living cell membranes, but it can pass through damaged cell membranes to stain the nucleus. Propidium Iodide has a fluorescence wavelength of 493/617 nm and a wavelength of 536/635 nm after Mosaic with DNA. Propidium Iodide is commonly used in the detection of apoptosis (apoptosis) or necrosis (necrosis), and is often used in flow cytometry analysis.
Fluorescent Dye   DNA/RNA Synthesis  
168
HY-18982 Anisomycin
Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. Anisomycin is a JNK activator, which increases phospho-JNK. Anisomycin is a bacterial antibiotic.

Source: Streptomyces griseolus

DNA/RNA Synthesis   JNK   Bacterial   Apoptosis   Antibiotic   Parasite  
Cancer   Digestive System Disease   Bacterial Infection   Parasitic Infection   Pain   Digestive System Inflammation  
163
HY-13753 Streptozotocin
Streptozotocin (Streptozocin; STZ) is an antibiotic widely used in experimental animal models of induced diabetes. Streptozotocin enters B cells via the glucose transporter (GLUT2) and causes the alkylation of DNA ( DNA-methylating ). Streptozotocin can induce the apoptosis of β cells.

Source: Streptomyces achromogenes

DNA/RNA Synthesis   DNA Alkylator/Crosslinker   Autophagy   Bacterial   Antibiotic   Apoptosis  
Cancer   Infection  
156
HY-13605 Cytarabine
Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine has antiviral effects against HSV. Cytarabine shows anti-orthopoxvirus activity.

Source: Xerocomus nigromaculatus

DNA/RNA Synthesis   Nucleoside Antimetabolite/Analog   HSV   Autophagy   Apoptosis   Endogenous Metabolite   Orthopoxvirus  
Neurological, Eye or Ear Disease   Digestive System Disease   Lung Cancer   Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation   Orthopoxvirus Infection   SARS-CoV-2 Infection  
106
HY-L005 Epigenetics Compound Library
Epigenetics refers to changes in phenotype that are not rooted in DNA sequence. Many types of epigenetic processes have been identified, including DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs. Modification of DNA, protein, or RNA, resulting in changes to the function and/or regulation of these molecules, without altering their primary sequences, reveals the complexities of cellular differentiation, embryology, the regulation of gene expression, aging, cancer, and other diseases. MCE provide a unique collection of 2,031 epigenetics-related compounds that can be used in the research of the related diseases.

Signaling Pathway Targeting Libraries

102
HY-17393 Carboplatin
Carboplatin (NSC 241240) is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death. Carboplatin (NSC 241240) is a derivative of CDDP and a potent anti-cancer agent.
DNA Alkylator/Crosslinker   Autophagy   DNA/RNA Synthesis  
99
HY-L036 Covalent Screening Library
Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery. MCE covalent inhibitor library contains 1,618 small molecules including identified covalent inhibitors and other bioactive molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, Sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc.

Structure Classified Libraries

87
HY-L005M Epigenetics Compound Library Mini
Epigenetics involves heritable phenotypic changes that occur without alterations to the underlying DNA sequence. Key mechanisms include DNA methylation, histone modifications, and regulation by small non-coding RNAs such as microRNAs. By modifying DNA, histones, or RNA—while leaving their primary sequences intact—these processes influence molecular function and regulation, thereby playing critical roles in cellular differentiation, embryonic development, gene expression control, aging, and diseases such as cancer. MCE provide a unique collection of 295 epigenetics-related compounds. For each regulatory target and its subtype, 3 to 5 highly specific representative compounds have been retained, which can be used in epigenetic and related disease research.

Signaling Pathway Targeting Libraries

83
HY-L036P Covalent Screening Library Plus
Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery. MCE covalent inhibitor library contains 6,121 small molecules including identified covalent inhibitors and other molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc. MCE Covalent inhibitor Library plus, with more powerful screening capability, further complement Covalent inhibitor Library (HY-L036) by adding some fragment compounds with covalent warheads.

Structure Classified Libraries

83
HY-L110 Cyclic Peptide Library
Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs. MCE offers a unique collection of 100 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

Structure Classified Libraries

83
HY-L230 FDA Kinase Inhibitor Library
Kinases are enzymes that catalyze the addition of phosphate groups to substrate molecules, a process known as phosphorylation. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes, including cell division, metabolism, and signal transduction. The human genome encodes over 500 kinases, which collectively regulate approximately 50% of cellular functions. Due to their pivotal roles, kinases represent one of the most important target classes in drug development. Kinase inhibitors can selectively block the activity of disease-associated kinases, making them valuable therapeutics for conditions such as cancer and inflammatory diseases. FDA-approved kinase inhibitors have undergone extensive preclinical and clinical studies, demonstrating high bioactivity, favorable safety profiles, and good bioavailability, rendering them suitable for investigating new therapeutic indications.
83
HY-L248 RNA Binding Bioactive Compound Library
The RNA-targeted bioactive compound library is a high-quality collection of small molecules specifically designed and curated to target RNA structures and functions. It is widely applied in cutting-edge drug discovery and life science research. Unlike traditional strategies that focus on protein targets, RNA-targeted compounds can directly modulate various functional RNA molecules by influencing their splicing, translation, stability, or structural conformation, thereby enabling precise intervention in key biological processes. In the field of drug development, these compounds provide a novel approach to addressing previously “undruggable” targets and have demonstrated significant potential in areas such as oncology, antiviral therapies, and neurodegenerative diseases. For example, by targeting disease-associated RNA structural domains or regulating the aberrant expression of non-coding RNAs, these compounds can effectively inhibit disease progression or restore normal cellular function. In mechanistic studies, RNA-targeted compounds serve as valuable chemical biology tools to elucidate the roles of RNA in gene expression regulation, cellular signaling pathways, and disease development. The MCE RNA-targeted bioactive compound library contains 858 compounds, sourced from databases such as TargetRX Atlas and R-BIND. The library features excellent structural diversity and biological activity, making it suitable for high-throughput screening (HTS), target validation, phenotypic screening, and lead compound discovery. It represents a valuable resource for RNA-related research and innovative drug development.

Signaling Pathway Targeting Libraries

83
HY-L249 Lactylation Compound Library
Protein lactylation, an emerging post-translational modification identified in recent years, plays a critical role in linking cellular metabolic reprogramming, epigenetic regulation, and signaling networks. Based on a systematic framework encompassing lactate metabolism, lactylation, and downstream signaling pathways, this compound library comprehensively targets multiple regulatory layers, including histone modification enzymes (such as p300 and HDACs), key glycolytic enzymes (such as PKM2, LDHA, and GAPDH), transcriptional regulators (such as STAT3, HMGB1, and p53), as well as central signaling pathway nodes including HIF-1α, NF-κB, and PI3K-AKT-mTOR. This integrated design enables a comprehensive representation of the regulatory roles of lactylation across the “metabolism–epigenetics–signaling” axis. MCE has assembled a collection of 6,182 known bioactive compounds and potential functional molecules, making this library suitable for a wide range of applications, including high-throughput drug screening, inhibitor identification, and mechanistic studies. It can be used to systematically evaluate the functional roles of lactylation in biological processes such as tumor metabolism, immune regulation, and inflammatory responses, and to efficiently identify small-molecule candidates with regulatory potential, thereby facilitating the development of innovative therapeutics targeting the interplay between metabolism and epigenetic regulation.

Signaling Pathway Targeting Libraries

83
HY-L251 Ionizable Lipid Compound Library
Ionizable lipids are a class of specialized, functional lipid molecules with pH-sensitive charge characteristics. They are primarily divided into two major categories: ionizable cationic lipids and ionizable anionic lipids, though the term typically specifies ionizable cationic lipids within the biomedical field. Structurally, these lipids consist of an ionizable hydrophilic headgroup, a biodegradable linker, and hydrophobic tails. Their primary application is serving as the key delivery vehicle in lipid nanoparticles (LNPs) to encapsulate negatively charged nucleic acid macromolecules, such as mRNA vaccines, siRNA therapeutics, and CRISPR gene-editing components. In a physiological, neutral environment, they remain electrically neutral to minimize systemic toxicity and prolong circulation time. Upon entering the acidic microenvironment of cellular endosomes, however, they undergo protonation to become positively charged, thereby inducing membrane fusion and enabling the highly efficient intracellular release of the nucleic acid cargo. Consequently, they serve as the technological cornerstone for bringing nucleic acid therapies into clinical application. To accelerate the translational process of cutting-edge nucleic acid drugs, MCE has meticulously constructed an ionizable lipid compound library containing 93 high-performance molecules, aiming to provide researchers and pharmaceutical professionals with a high-throughput, multi-dimensional lipid screening platform.

Structure Classified Libraries

83
HY-L908 Lead-like Covalent Screening Library
Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery. MCE Lead-like Covalent Screening Library offers a valuable resource of 1,049 lead-like compounds with commonly used covalent warheads. These warheads, such as acrylamide, activated terminal alkyne, acyloxymethyl ketone, and boronic acid, are capable of reacting with specific amino acid residues, including cysteine, lysine, serine, and histidine. The inclusion of these reactive warheads in the library allows researchers to explore the potential of covalent inhibition, a powerful approach in drug discovery.

According to Lead-like Structures

83
HY-16560 Camptothecin
Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.
Topoisomerase   ADC Payloads   MicroRNA   Influenza Virus   Apoptosis   Fungal   Antibiotic  
Lung Cancer   Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Fungal Infection   Digestive System Inflammation  
75
HY-112654 GCN2iB
GCN2iB is an ATP-competitive, selective GCN2 inhibitor with an IC50 of 2.4 nM. GCN2iB inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy.
Eukaryotic Initiation Factor (eIF)   Glutathione Peroxidase  
Glucose Metabolism   Acute Myeloid Leukemia   Acute Lymphoblastic Leukemia   Cardiomyopathy  
65
HY-13251 Silvestrol
Silvestrol is a eukaryotic translation initiation factor 4A (eIF4A) inhibitor isolated from Agave americana Linn.. Silvestrol induces autophagy and caspase-mediated apoptosis.
Eukaryotic Initiation Factor (eIF)   Apoptosis   Autophagy  
54
HY-12495A ISRIB
ISRIB is a brain-penetrant inhibitor of integrated stress response (ISR). Persistent activation of the ISR has been linked to the development of several neurological disorders as ISR represses translation through inhibiting eIF2B. ISRIB inhibits the ISR by promoting the nucleotide exchange activity of eIF2B and recovering the translation, and thus can be used for neurological disorders research.
Biochemical Assay Reagents   Eukaryotic Initiation Factor (eIF)  
Neurological, Eye or Ear Disease  
37
HY-19356 Rocaglamide
Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC50 of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia.
NF-κB   HSP   Eukaryotic Initiation Factor (eIF)  
Inflammation or Immune System Disease  
32
HY-100877 GCN2-IN-1
GCN2-IN-1 is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with an IC50 of <0.3 μM in the enzyme assay and an IC50 of 0.3-3 μM in the cell assay.
Eukaryotic Initiation Factor (eIF)  
Cancer  
27
HY-100574A Cl-amidine hydrochloride
Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine hydrochloride induces apoptosis in cancer cells. Cl-amidine hydrochloride induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine hydrochloride prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model.
Protein Arginine Deiminase   Apoptosis   MicroRNA  
Cancer   Digestive System Disease   Digestive System Inflammation  
27
HY-R04602 MicroRNA Mimic Negative Control
MicroRNA Mimic Negative Control is a miRNA mimic of 21-nucleotides, and can be used as a negative control. The sequence of MicroRNA Mimic Negative Control is derived from cel-mir-239b. It has minimal sequence identity with miRNAs in human, mouse, and rat.
MicroRNA  
Cancer  
19
HY-19831 4EGI-1
4EGI-1 is an inhibitor of eIF4E/eIF4G interaction, with a Kd of 25 μM against eIF4E binding.
Eukaryotic Initiation Factor (eIF)   Autophagy   Apoptosis  
Digestive System Disease   Breast Cancer   Digestive System Inflammation  
18
HY-RI04602 MicroRNA Inhibitor Negative Control
MicroRNA Inhibitor Negative Control is a full-length nucleotide 2'-methoxy modified oligonucleotide, and can be used as a negative control. The sequence of MicroRNA Inhibitor Negative Control is derived from cel-mir-239b. It has minimal sequence identity with miRNAs in human, mouse, and rat.
MicroRNA  
14
HY-N0177 Diosgenin
Diosgenin, a steroidal saponin, can inhibit STAT3 signaling pathway. Diosgenin is an exogenous activator of Pdia3/ERp57. Diosgenin inhibits aortic atherosclerosis progression by suppressing macrophage miR-19b expression.
STAT   MicroRNA  
Inflammation or Immune System Disease   Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Glucose Metabolism   Obesity  
11
HY-112163 Zotatifin
Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC50=2 nM) and interferes with the assembly of the eIF4F initiation complex. Zotatifin shows robust antiviral effects, it effectively reduces viral infectivity by inhibiting SARS-CoV-2 NP protein biogenesis (IC90=37 nM). Zotatifin induces cell apoptosis.
Eukaryotic Initiation Factor (eIF)   SARS-CoV   Apoptosis  
10
HY-W017443 L-Asparagine monohydrate
L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease   Digestive System Disease   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation  
5
HY-122575 Aurintricarboxylic acid
Aurintricarboxylic acid is a nanomolar-potency, allosteric antagonist with selectivity towards αβ-methylene-ATP-sensitive P2X1Rs and P2X3Rs, with IC50s of 8.6 nM and 72.9 nM for rP2X1R and rP2X3R, respectively. Aurintricarboxylic acid is a potent anti-influenza agent by directly inhibiting the neuraminidase. Aurintricarboxylic acid is an inhibitor of topoisomerase II and apoptosis. Aurintricarboxylic acid is a selective inhibitor of the TWEAK-Fn14 signaling pathway. Aurintricarboxylic acid also acts as a cystathionine-lyase (CSE) inhibitor with an IC50 of 0.6 μM. Aurintricarboxylic acid is a modifier of miRNAs that regulate miRNA function, with an IC50 of 0.47 µM.
P2X Receptor   Influenza Virus   Topoisomerase   MicroRNA   Apoptosis  
Neurological, Eye or Ear Disease   Digestive System Disease   Lung Cancer   Leukemia/Lymphoma/Myeloma   Viral Infection   Digestive System Inflammation  
5
HY-N0401A (Z)-Ligustilide
(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6. (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer.
Bacterial   Estrogen Receptor/ERR   FATP  
Infection   Metabolic or Endocrine Disease   Breast Cancer  
5
HY-N0667 L-Asparagine
L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Cancer   Digestive System Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
5
HY-125021 2BAct
2BAct is a highly selective, orally active, and CNS-penetrant eIF2B (eukaryotic initiation factor 2B) activator with an EC50 of 33 nM. 2BAct prevents neurological defects caused by a chronic integrated stress response. 2BAct displays improved solubility and pharmacokinetics relative to eIF2B activator ISRIB trans-isomer (HY-12495).
Eukaryotic Initiation Factor (eIF)  
Neurological, Eye or Ear Disease  
4
HY-RI04602A MicroRNA Antagomir Negative Control
MicroRNA Antagomir Negative Control is a chemically-modified oligonucleotide (2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification), and can be used as a negative control. The sequence of MicroRNA Antagomir Negative Control is derived from cel-mir-239b. It has minimal sequence identity with miRNAs in human, mouse, and rat.
MicroRNA  
3
HY-KE7055 RNase R

RNase R is a magnesium ion-dependent 3'-5' exoribonuclease that can increase the abundance of circular RNA by degrading linear RNA in mixed RNA, thereby enriching circular RNA.

Molecular Biology Restriction Endonuclease

3
HY-14307 Necrocide 1
Necrocide 1, a necrosis by sodium overload (NECSO) inducer, is a selective transient receptor potential melastatin 4 (TRPM4) agonist with an EC50 of 306.3 nM for human TRPM4. Necrocide 1 triggers TRPM4-dependent necrotic cell death through the induction of sodium influx. Necrocide 1 induces hallmarks of immunogenic cell death incurring calreticulin (CALR) exposure, ATP secretion and high mobility group box 1 (HMGB1) release. Necrocide 1 can be used for the study of breast and prostate cancer.
TRP Channel   Eukaryotic Initiation Factor (eIF)   Reactive Oxygen Species (ROS)  
Prostate Cancer   Pain  
2
HY-N0667S5 L-Asparagine-d3 hydrate
L-Asparagine-d3 hydrate is the deuterium labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
1
HY-N0667S2 L-Asparagine-15N2 monohydrate
L-Asparagine-15N2 monohydrate is the 15N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
1
HY-W176171 PU.1-IN-1
PU.1-IN-1 is a potent PU.1 inhibitor with an IC50 of 2 nM. PU.1-IN-1 reduces rMANF-induced miR-223 expression. PU.1-IN-1 exhibits anti-inflammatory properties.
MicroRNA  
Inflammation or Immune System Disease  
1
HY-139290 RGLS4326
RGLS4326 (RG4326) is a first-in-class, short oligonucleotide inhibitor of microRNA-17 (miR-17). RGLS4326 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 inhibits miR-17 function in HeLa cells with an EC50 value of 28.3 nM.
MicroRNA  
Cancer   Metabolic or Endocrine Disease  
1
HY-N3005 Britannin
Britannin is an NLRP3 inhibitor with an IC50 of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the NLRP3 inflammasome by blocking the interaction between NLRP3 and NEK7. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics.
Apoptosis   Autophagy   NOD-like Receptor (NLR)   Pyroptosis  
Prostate Cancer   Liver Cancer   Depression   Autoimmune Disease   Digestive System Inflammation  
1
HY-113061 Pseudouridine
Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation. Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia..
Endogenous Metabolite   Nucleoside Antimetabolite/Analog   DNA/RNA Synthesis  
Lung Cancer   Leukemia/Lymphoma/Myeloma  
1
HY-108666 ATPγS tetralithium salt
ATPγS (tetralithium salt) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATPγS (tetralithium salt) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATPγS (tetralithium salt) is active in ATP hydrolysis.
Eukaryotic Initiation Factor (eIF)   P2Y Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-W768571 Pseudouridine-13C,15N2
Pseudouridine-13C,15N2 is the 13C- and 15N-labeled Pseudouridine (HY-113061). Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation. Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia..
Isotope-Labeled Compounds   Endogenous Metabolite   DNA/RNA Synthesis   Nucleoside Antimetabolite/Analog  
Cancer  
/
HY-P2342 Angiopep-Bim BH3 hydrochloride
Angiopep-Bim BH3 hydrochloride, a BBB penetrated peptode, could be used to investigate the permeability of CNS therapeutics.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-N0667S4 L-Asparagine-4-13C monohydrate
L-Asparagine-4-13C monohydrate is the 13C-labeled L-Asparagine monohydrate (HY-W017443).L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
/
HY-113061S Pseudouridine-O18
Pseudouridine-18O is the 18O labeled Pseudouridine (HY-113061). Pseudouridine is an isomer of the nucleoside uridine, and the most abundant modified nucleoside in non-coding RNAs. Pseudouridine in rRNA and tRNA can fine-tune and stabilize the regional structure and help maintain their functions in mRNA decoding, ribosome assembly, processing and translation.
Isotope-Labeled Compounds   Endogenous Metabolite   Nucleoside Antimetabolite/Analog   DNA/RNA Synthesis  
/
HY-W017443R L-Asparagine monohydrate (Standard)
L-Asparagine monohydrate (Standard) is the analytical standard of L-Asparagine monohydrate (HY-W017443). This product is intended for research and analytical applications. L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Reference Standards   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-D1409 DMTr-4'-F-U-CED-TBDMS phosphoramidite
DMTr-4'-F-U-CED-TBDMS phosphoramidite (DMTr-4'-F-uridine-CED-TBDMS phosphoramidite), a dye reagent for oligonucleotide labeling, can be used for the research of applications in RNA therapeutics, RNA aptamers, and ribozymes for elucidating RNA structure. DMTr-4'-F-U-CED-TBDMS phosphoramidite represents a probe with wide utility for elucidation of RNA structure.
DNA Stain   Phosphoramidites  
Blood or Cardio-cerebrovascular Disease  
/
HY-101112 Okicenone
Okicenone is a Hu protein R (HuR) inhibitor. Okicenone inhibits HuR oligomerization, interferes with HuR RNA binding, HuR trafficking, cytokine expression and T-cell activation.

Source: Streptomyces

HuR  
Inflammation or Immune System Disease  
/
HY-P5415 DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS
DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS is a biological active peptide. (DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS is also called HIV protease substrate I in some literature. It is widely used for the continuous assay for HIV protease activity. The 11-Kd protease (PR) encoded by the human immunodeficiency virus 1 (HIV-1) is essential for the correct processing of viral polyproteins and the maturation of infectious virus, and is therefore a target for the design of selective acquired immunodeficiency syndrome (AIDS) therapeutics. The FRET-based fluorogenic substrate is derived from a natural processing site for HIV-1 PR. Incubation of recombinant HIV-1 PR with the fluorogenic substrate resulted in specific cleavage at the Tyr-Pro bond and a time-dependent increase in fluorescence intensity that is linearly related to the extent of substrate hydrolysis. The fluorescence quantum yields of the HIV-1 PR substrate in the FRET assay increased by 40.0- and 34.4-fold, respectively, per mole of substrate cleaved. Because of its simplicity and precision in the determination of reaction rates required for kinetic analysis, this substrate offers many advantages over the commonly used HPLC or electrophoresis-based assays for peptide substrate hydrolysis by retroviral PRs. Abs/Em = 340nm/490nm.)
HIV  
/
HY-N0667S7 L-Asparagine-13C4,15N2
L-Asparagine-13C4,15N2 ((-)-Asparagine-13C4,15N2) is the 13C and 15N-labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Cancer   Inflammation or Immune System Disease  
/
HY-P11351 Precursor-HhH
Precursor-HhH is a nucleic acid-binding peptide capable of non-specific interactions with RNA and double-stranded DNA (dsDNA). Precursor-HhH is promising for research of nucleic acid-targeted therapeutics.
DNA/RNA Synthesis  
Cancer  
/
HY-D1408 DMTr-4'-Me-U-CED-TBDMS phosphoramidite
DMTr-4'-Me-U-CED-TBDMS phosphoramidite (DMTr-4'-Methyluridine-CED-TBDMS phosphoramidite), a dye reagent for oligonucleotide labeling, can be used for the research of applications in RNA therapeutics, RNA aptamers, and ribozymes for elucidating RNA structure. DMTr-4'-Me-U-CED-TBDMS phosphoramidite represents a probe with wide utility for elucidation of RNA structure.
DNA Stain   Phosphoramidites  
Blood or Cardio-cerebrovascular Disease  
/
HY-P3103 PINT-87aa
PINT-87aa, an 87-amino acid (aa) peptide, is encoded by the circular form of the long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT). PINT-87aa directly interacts with polymerase associated factor complex (PAF1c) and inhibits the transcriptional elongation of multiple oncogenes. PINT-87aa suppresses glioblastoma cell proliferation in vitro and in vivo.
DNA/RNA Synthesis  
/
HY-B0268S2 Enoxacin-d8 hydrate
Enoxacin-d8 (hydrate) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 μg/ml) and topoisomerase IV (IC50=26.5 μg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
Isotope-Labeled Compounds   DNA/RNA Synthesis   MicroRNA   Antibiotic   Bacterial  
Cancer   Infection  
/
HY-118747 Scirpusin A
Scirpusin A is a naturally occurring compound extracted from the legume plant Caragana rosea Turcz, exhibiting anti-HIV activity. Scirpusin A demonstrates significant inhibitory effects against HIV-1 (EC50=7 μg/mL). Scirpusin A is utilized in research towards the development of anti-HIV therapeutics.
HIV  
Infection  
/
HY-N15345 Menominin A
Menominin A is a cyclic peptide identified from the freshwater sponge-associated cyanobacterium Nostoc sp., exhibiting cytotoxic properties. It displays antiproliferative activity against the ovarian cancer cell line OVCAR3, with an IC50 value of 3.1 μM. Menominin A holds promise for research in the field of anticancer therapeutics.

Source: Freshwater Sponge-Associated Cyanobacterium Nostoc sp. UIC 10607

Others  
/
HY-N0667S1 L-Asparagine-15N2,d8
L-Asparagine-15N2,d8 is the 15N- and deuterium labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
/
HY-P5117 TAT-CIRP
TAT-CIRP is a a small peptide, refers to Trans-trans-activating (Tat)-cold-inducible RNA binding protein. TAT-CIRP is an inhibitor of myeloid differentiation protein 2 (MD2). TAT-CIRP exhibits robust neuroprotection against ischemic and hemorrhagic stroke in mice.
Toll-like Receptor (TLR)  
Neurological, Eye or Ear Disease  
/
HY-134541G SM-102 (GMP)
SM-102 (GMP) is SM-102 (HY-134541) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SM-102 is an amino cationic lipid useful in the formation of lipid nanoparticles (LNPs). SM-102 has higher transfection efficiency. SM-102 plays an important role in the effectiveness of lipid nanoparticles (LNPs) in delivering mRNA therapeutics and vaccines.
Liposome  
Infection  
/
HY-N0667S L-Asparagine-13C4,15N2,d8
L-Asparagine-13C4,15N2,d8 is the 13C-labeled and 15N-labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
/
HY-P3103A PINT-87aa TFA
PINT-87aa TFA, an 87-amino acid (aa) peptide, is encoded by the circular form of the long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT). PINT-87aa TFA directly interacts with polymerase associated factor complex (PAF1c) and inhibits the transcriptional elongation of multiple oncogenes. PINT-87aa TFA suppresses glioblastoma cell proliferation in vitro and in vivo.
DNA/RNA Synthesis  
/
HY-W017443S1 L-Asparagine-amide-15N monohydrate
L-Asparagine-amide-15N monohydrate is the 15N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-B0268S1 Enoxacin-d8 hydrochloride
Enoxacin-d8 (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 μg/ml) and topoisomerase IV (IC50=26.5 μg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
Isotope-Labeled Compounds   Bacterial   DNA/RNA Synthesis   MicroRNA   Antibiotic  
Cancer   Infection  
/
HY-W017443S2 L-Asparagine-13C4,15N2,d3 monohydrate
L-Asparagine-13C4,15N2,d3 monohydrate is the deuterium, 13C-, and 15N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-113061R Pseudouridine (Standard)
Pseudouridine (Standard) is the analytical standard of Pseudouridine. This product is intended for research and analytical applications. Pseudouridine is an isomer of the nucleoside uridine, and the most abundant modified nucleoside in non-coding RNAs. Pseudouridine in rRNA and tRNA can fine-tune and stabilize the regional structure and help maintain their functions in mRNA decoding, ribosome assembly, processing and translation[4].
Reference Standards   Endogenous Metabolite   Nucleoside Antimetabolite/Analog   DNA/RNA Synthesis  
/
HY-134541GL SM-102 (GMP Like)
SM-102 (GMP Like) is SM-102 (HY-134541) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SM-102 is an amino cationic lipid useful in the formation of lipid nanoparticles (LNPs). SM-102 has higher transfection efficiency. SM-102 plays an important role in the effectiveness of lipid nanoparticles (LNPs) in delivering mRNA therapeutics and vaccines.
Liposome  
Infection  
/
HY-N0667R L-Asparagine (Standard)
L-Asparagine (Standard) is the analytical standard of L-Asparagine (HY-N0667). This product is intended for research and analytical applications. L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Reference Standards   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Cancer   Inflammation or Immune System Disease  
/
HY-P10557 DAG peptide
DAG peptide is a cyclic peptide. DAG peptide selectively recognizes a subset of astrocytes that are activated in Alzheimer's disease (AD) starting at an early stage of the disease. DAG peptide can be used as a tool to enhance the delivery of therapeutics and imaging agents to sites of vascular changes and astrogliosis in diseases associated with neuroinflammation.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-W017443S L-Asparagine-13C4,15N2 monohydrate
L-Asparagine-13C4,15N2 monohydrateis the 13C-labeled and 15N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N0667S3 L-Asparagine-13C4 monohydrate
L-Asparagine-13C4 monohydrate is the 13C-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
/
HY-130413 Protectin D1
Protectin D1, a neuroprotectin D1 produced by neuronal cells, is a member of a newly discovered family of bioactive products derived from docosahexaenoic acid. Protectin D1 also serves as a specialized pro-resolving mediator, exhibiting effective in vivo pro-resolving activity in various human disease models. Additionally, Protectin D1 is an inhibitor of NALP3 inflammasomes and regulates the PI3K/AKT and HIF-1α signaling pathways. Protectin D1 exerts anti-inflammatory effects by reducing ROS levels, inhibiting the expression of NALP3, ASC, and Caspase-1, and consequently decreasing the release of pro-inflammatory cytokines IL-1β and IL-18. Furthermore, Protectin D1 enhances miRNA-210 expression, activates the PI3K/AKT signaling pathway, and exerts cardioprotective effects. Protectin D1 holds promise for research in cardiovascular diseases and inflammatory disorders.
Endogenous Metabolite   PI3K   Akt   HIF/HIF Prolyl-Hydroxylase   Reactive Oxygen Species (ROS)   Caspase   Interleukin Related   MicroRNA  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P73024 Ephrin-A1/EFNA1 Protein, Mouse (HEK293, His)
The Ephrin-A1/EFNA1 protein is a GPI-binding ligand critical for migration, repulsion, and adhesion in developing neurons, blood vessels, and epithelia. It binds to nearby Eph receptors, initiating bidirectional signaling. Ephrin-A1/EFNA1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Ephrin-A1/EFNA1 protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors Ephrin/Eph Family Ephrins Ephrin-A1

/

Keywords

circular RNA | circRNA | back-splicing | RNA biomarkers | noncoding RNA | microRNA binding | RNA-binding proteins | circRNA therapeutics